Immune thrombocytopenia induced by vonoprazan fumarate: a single center retrospective study
- 279 Downloads
Vonoprazan fumarate is a first-in-class potassium-competitive acid blocker developed in Japan. Compared with conventional proton-pump inhibitors (PPI), vonoprazan is absorbed rapidly and reaches maximum plasma concentration shortly after oral administration because activation by gastric acid is no longer required . It is approved for treatment in gastroduodenal ulcers, reflux esophagitis, and Helicobacter pylori eradication [2, 3, 4]. Drugs can cause thrombocytopenia by several mechanisms, including drug-induced immune thrombocytopenia (DITP): an antibody-mediated platelet destruction caused by exposure to a drug . DITP due to PPI has been described previously [6, 7, 8]; however, no studies have examined induction of thrombocytopenia by vonoprazan exposure. We report a retrospective study on immune thrombocytopenia caused by vonoprazan.
Compliance with ethical standards
Informed consent was obtained from the patient for publication. This study was performed in conformity with the Declaration of Helsinki and was approved by our ethical committee.
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Maruoka D, Arai M, Kasamatsu S, Ishigami H, Taida T, Okimoto K, Saito K, Matsumura T, Nakagawa T, Katsuno T, Yokosuka O (2017) Vonoprazan is superior to proton pump inhibitors in healing artificial ulcers of the stomach post-endoscopic submucosal dissection: a propensity score-matching analysis. Dig Endosc 29(1):57–64. https://doi.org/10.1111/den.12705 CrossRefPubMedGoogle Scholar
- 3.Ashida K, Sakurai Y, Hori T, Kudou K, Nishimura A, Hiramatsu N, Umegaki E, Iwakiri K (2016) Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther 43(2):240–251. https://doi.org/10.1111/apt.13461 CrossRefPubMedGoogle Scholar
- 4.Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M (2016) Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 65(9):1439–1446. https://doi.org/10.1136/gutjnl-2015-311304 CrossRefPubMedPubMedCentralGoogle Scholar